Skip to main content

Advertisement

Log in

Intrathecal mitozantrone has to be prohibited

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2

References

  1. Laporte JP, Godefroy W, Verny A, Gorin NC, Najman A, Duhamel G . Intrathecal mitozantrone Lancet 1985 ii: 160

    Article  Google Scholar 

  2. Zuiable A, Maitland J, Nandi A, Clink HM, Powles RL . Intrathecal mitozantrone for resistant leukemia Lancet 1985 ii: 1060–1061

    Article  Google Scholar 

  3. Lakhani AK, Zuiable AG, Pollard CM, Milne A, Treleaven J, Powles RL . Paraplegia after intrathecal mitozantrone Lancet 1986 ii: 1393

    Article  Google Scholar 

  4. Man A, Brock PG . Intrathecal mitozantrone Lancet 1987 i: 327

    Article  Google Scholar 

  5. Hywel W, Pembroke A . Warning against use of intrathecal mitozantrone Lancet 1989 i: 734

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalle, J., Lambilliotte, A., Defachelles, A. et al. Intrathecal mitozantrone has to be prohibited. Leukemia 14, 2323–2324 (2000). https://doi.org/10.1038/sj.leu.2401957

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401957

  • Springer Nature Limited

Navigation